Shizuoka, Japan

Hiroko Ogawa

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 17.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2020-2025

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):

Title: Hiroko Ogawa: Innovator in Diabetes Treatment

Introduction

Hiroko Ogawa is a prominent inventor based in Shizuoka, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for diabetes and obesity. With a total of seven patents to her name, Ogawa's work is recognized for its innovative approach to addressing critical health issues.

Latest Patents

One of her latest patents includes a pyrazolopyridine derivative that exhibits a GLP-1 receptor agonist effect. This invention provides a compound characterized by a specific structural formula, where the indole ring and the pyrazolopyridine structure are interconnected through a substituent. The patent outlines the compound's potential as a preventative or therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) and obesity, highlighting its active ingredients.

Career Highlights

Hiroko Ogawa is currently employed at Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. Her work at Chugai has allowed her to focus on innovative drug development, contributing to advancements in medical treatments. Ogawa's dedication to her field has positioned her as a key figure in pharmaceutical research.

Collaborations

Throughout her career, Ogawa has collaborated with notable colleagues, including Satoshi Tsuchiya and Atsushi Matsuo. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Hiroko Ogawa's contributions to the field of diabetes treatment through her innovative patents and collaborative efforts underscore her importance as an inventor. Her work continues to impact the pharmaceutical industry positively, paving the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…